Long-term treatment of rheumatoid arthritis with adalimumab

Giuseppe Murdaca, Francesca Spanò, Francesco PuppoDepartment of Internal Medicine, Clinical Immunology Unit, University of Genoa, Genoa, ItalyAbstract: Rheumatoid arthritis (RA) is a chronic inflammatory disease that is associated with joint damage and progressive disability, an increased...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Murdaca G, Spano F, Puppo F
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/15696d463d87450fb6f77dc0f7913dd6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:15696d463d87450fb6f77dc0f7913dd6
record_format	dspace
spelling	oai:doaj.org-article:15696d463d87450fb6f77dc0f7913dd62021-12-02T01:11:15ZLong-term treatment of rheumatoid arthritis with adalimumab1179-156Xhttps://doaj.org/article/15696d463d87450fb6f77dc0f7913dd62013-05-01T00:00:00Zhttp://www.dovepress.com/long-term-treatment-of-rheumatoid-arthritis-with-adalimumab-a13001https://doaj.org/toc/1179-156XGiuseppe Murdaca, Francesca Spanò, Francesco PuppoDepartment of Internal Medicine, Clinical Immunology Unit, University of Genoa, Genoa, ItalyAbstract: Rheumatoid arthritis (RA) is a chronic inflammatory disease that is associated with joint damage and progressive disability, an increased risk of morbidity related to comorbid conditions and substantial socioeconomic costs. Tumor necrosis factor-alpha (TNF-α) is a proinflammatory cytokine known to have a central role in the initial host response to infection and in the pathogenesis of various immune-mediated diseases, such as RA, ankylosing spondylitis, psoriasis and/or psoriatic arthritis, Crohn’s disease, and systemic lupus erythematosus. Five TNF-α inhibitors are available for the clinical use: infliximab; adalimumab; etanercept; golimumab; and certolizumab pegol. Infliximab is a chimeric human/murine IgG1 monoclonal antibody (mAb); adalimumab, and golimumab are human mAbs; certolizumab pegol is composed of the fragment antigen-binding anti-binding domain of a humanized anti-TNF-α mAb, combined with polyethylene glycol to increase its half-life in the body; etanercept is a fusion protein that acts as a “decoy receptor” for TNF-α. In this paper, we will briefly review the current data on efficacy and safety of adalimumab in patients with RA, its potential beneficial effects upon comorbid conditions, such as endothelial dysfunction and accelerated atherosclerosis in RA, and the immunogenicity.Keywords: adalimumab, efficacy, safety, rheumatoid arthritis, VEGF, immunogenicity, infectionsMurdaca GSpano FPuppo FDove Medical PressarticleDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol 2013, Iss default, Pp 43-49 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the musculoskeletal system RC925-935
spellingShingle	Diseases of the musculoskeletal system RC925-935 Murdaca G Spano F Puppo F Long-term treatment of rheumatoid arthritis with adalimumab
description	Giuseppe Murdaca, Francesca Spanò, Francesco PuppoDepartment of Internal Medicine, Clinical Immunology Unit, University of Genoa, Genoa, ItalyAbstract: Rheumatoid arthritis (RA) is a chronic inflammatory disease that is associated with joint damage and progressive disability, an increased risk of morbidity related to comorbid conditions and substantial socioeconomic costs. Tumor necrosis factor-alpha (TNF-α) is a proinflammatory cytokine known to have a central role in the initial host response to infection and in the pathogenesis of various immune-mediated diseases, such as RA, ankylosing spondylitis, psoriasis and/or psoriatic arthritis, Crohn’s disease, and systemic lupus erythematosus. Five TNF-α inhibitors are available for the clinical use: infliximab; adalimumab; etanercept; golimumab; and certolizumab pegol. Infliximab is a chimeric human/murine IgG1 monoclonal antibody (mAb); adalimumab, and golimumab are human mAbs; certolizumab pegol is composed of the fragment antigen-binding anti-binding domain of a humanized anti-TNF-α mAb, combined with polyethylene glycol to increase its half-life in the body; etanercept is a fusion protein that acts as a “decoy receptor” for TNF-α. In this paper, we will briefly review the current data on efficacy and safety of adalimumab in patients with RA, its potential beneficial effects upon comorbid conditions, such as endothelial dysfunction and accelerated atherosclerosis in RA, and the immunogenicity.Keywords: adalimumab, efficacy, safety, rheumatoid arthritis, VEGF, immunogenicity, infections
format	article
author	Murdaca G Spano F Puppo F
author_facet	Murdaca G Spano F Puppo F
author_sort	Murdaca G
title	Long-term treatment of rheumatoid arthritis with adalimumab
title_short	Long-term treatment of rheumatoid arthritis with adalimumab
title_full	Long-term treatment of rheumatoid arthritis with adalimumab
title_fullStr	Long-term treatment of rheumatoid arthritis with adalimumab
title_full_unstemmed	Long-term treatment of rheumatoid arthritis with adalimumab
title_sort	long-term treatment of rheumatoid arthritis with adalimumab
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/15696d463d87450fb6f77dc0f7913dd6
work_keys_str_mv	AT murdacag longtermtreatmentofrheumatoidarthritiswithadalimumab AT spanof longtermtreatmentofrheumatoidarthritiswithadalimumab AT puppof longtermtreatmentofrheumatoidarthritiswithadalimumab
_version_	1718403240292253696

Long-term treatment of rheumatoid arthritis with adalimumab

Ejemplares similares